New Alzheimer's drug enters early safety testing

NCT ID NCT07234942

Recruiting now Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Nov 19, 2025 · Last updated May 08, 2026 · Updated 24 times

Summary

This early-stage study tests a new drug called RO7812653 in about 50 people with early Alzheimer's disease. The main goal is to check if the drug is safe and how the body handles it. Participants receive a single dose injected into the spine and are closely monitored for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Brain Research Center Amsterdam
RECRUITING

Amsterdam, North Holland, 1081 HV, Netherlands
Institute of Psychiatry, Psychology and Neuroscience;Department of Old Age Psychiatry
RECRUITING

London, Greater London, SE5 8AF, United Kingdom
Karolinska Universitetssjukhuset
RECRUITING

Solna, 171 76, Sweden
National Hospital For Neurology and Neurosurgery
RECRUITING

London, WC1N 3BG, United Kingdom
Sahlgrenska Universitetssjukhuset
RECRUITING

Mlndal, 43180, Sweden
Southampton General Hospital
RECRUITING

Southampton, Hampshire, SO16 6YD, United Kingdom

Conditions

Explore the condition pages connected to this study.

ALZHEIMER S DISEASE